Millipore Sigma Vibrant Logo

475889 MK-886 - CAS 118414-82-7 - Calbiochem

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
118414-82-7C₂₇H₃₃ClNO₂S · Na

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
475889-5MG
Récupération des données relatives à la disponibilité...
Disponibilité limitée
Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Ampoule plast. 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewA cell-permeable, orally active NSAID (nonsteroidal antiinflammatory drug) that blocks cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2, activity (IC50 = 8, 2, and 58 µM, respectively), as well as suppresses cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (<10% by 1 µM MK-886). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, MK-886 does not cause gastrointestinal damages when applied in vivo.
      Catalogue Number475889
      Brand Family Calbiochem®
      Synonyms3-[1-(p-Chlorobenzyl)-5-(isopropyl)-3-t-butylthioindol-2-yl]-2,2-dimethylpropanoic Acid, Na, COX-1 Inhibitor III, FLAP Inhibitor I, MK886, mPGES-1 Inhibitor I
      References
      ReferencesKoeberle, A., et al. 2009. Eur. J. Pharmacol. 608, 84.
      Koeberle, A., et al. 2008. J. Pharmacol. Exp. Ther. 326, 975.
      Fisher, L., et al. 2007. Br. J. Pharmacol. 152, 471.
      Ford-Hutchinson, A.W., et al. 1993. Can. J. Physiol. Pharmacol. 71, 806.
      Ford-Hutchinson, A.W. 1991. Trends Pharmacol. 12, 68.
      Dixon, R.A., et al. 1990. Nature 343, 282.
      Rouzer, C.A., et al. 1990. J. Biol. Chem. 265, 1436.
      Product Information
      CAS number118414-82-7
      ATP CompetitiveN
      FormWhite solid
      Hill FormulaC₂₇H₃₃ClNO₂S · Na
      Chemical formulaC₂₇H₃₃ClNO₂S · Na
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetleukotreine biosybthesis
      Primary Target IC<sub>50</sub>102 nM
      Purity≥99% by TLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +15°C to +30°C
      Do not freeze Ok to freeze
      Special InstructionsUnstable in solution; reconstitute just prior to use.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      475889-5MG 04055977203592

      Documentation

      MK-886 - CAS 118414-82-7 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      MK-886 - CAS 118414-82-7 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      475889

      Références bibliographiques

      Aperçu de la référence bibliographique
      Koeberle, A., et al. 2009. Eur. J. Pharmacol. 608, 84.
      Koeberle, A., et al. 2008. J. Pharmacol. Exp. Ther. 326, 975.
      Fisher, L., et al. 2007. Br. J. Pharmacol. 152, 471.
      Ford-Hutchinson, A.W., et al. 1993. Can. J. Physiol. Pharmacol. 71, 806.
      Ford-Hutchinson, A.W. 1991. Trends Pharmacol. 12, 68.
      Dixon, R.A., et al. 1990. Nature 343, 282.
      Rouzer, C.A., et al. 1990. J. Biol. Chem. 265, 1436.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision21-January-2013 JSW
      Synonyms3-[1-(p-Chlorobenzyl)-5-(isopropyl)-3-t-butylthioindol-2-yl]-2,2-dimethylpropanoic Acid, Na, COX-1 Inhibitor III, FLAP Inhibitor I, MK886, mPGES-1 Inhibitor I
      DescriptionA cell-permeable, orally active NSAID (nonsteroidal antiinflammatory drug) that blocks cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2, activity (IC50 = 8, 2, and 58 µM, respectively), as well as suppresses cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (<10% by 1 µM MK-886). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, MK-886 does not cause gastrointestinal damages when applied in vivo.
      FormWhite solid
      CAS number118414-82-7
      Chemical formulaC₂₇H₃₃ClNO₂S · Na
      Structure formulaStructure formula
      Purity≥99% by TLC
      SolubilityDMSO (25 mg/ml) or Ethanol (25 mg/ml)
      Storage +15°C to +30°C
      Do Not Freeze Ok to freeze
      Special InstructionsUnstable in solution; reconstitute just prior to use.
      Toxicity Standard Handling
      ReferencesKoeberle, A., et al. 2009. Eur. J. Pharmacol. 608, 84.
      Koeberle, A., et al. 2008. J. Pharmacol. Exp. Ther. 326, 975.
      Fisher, L., et al. 2007. Br. J. Pharmacol. 152, 471.
      Ford-Hutchinson, A.W., et al. 1993. Can. J. Physiol. Pharmacol. 71, 806.
      Ford-Hutchinson, A.W. 1991. Trends Pharmacol. 12, 68.
      Dixon, R.A., et al. 1990. Nature 343, 282.
      Rouzer, C.A., et al. 1990. J. Biol. Chem. 265, 1436.